Floatz logo

Sgn-Cd19A

Precursor B-cell Lymphoblastic Leukemia-Lymphoma

Seagen Inc.Phase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Precursor B-cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Sgn-Cd19A is also rated in:

Burkitt lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →